Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 14/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL355839 | 0.86 | TDP1 (0.53) | ERN1PTGS2TDP1 | |
| SCHEMBL11872397 | 0.82 | TDP1 (0.67) | ERN1TDP1 | |
| SCHEMBL8035343 | 0.79 | TDP1 (0.53) | ERN1TDP1 | |
| SCHEMBL609449 | 0.78 | TDP1 (0.69) | ERN1TDP1 | |
| SCHEMBL1547171 | 0.77 | TDP1 (0.55) | ERN1TDP1 | |
| SCHEMBL15674737 | 0.77 | ERN1 (0.61) | ERN1 | |
| SCHEMBL904087 | 0.76 | ESR2 (0.56) | PTGS2PTGS1 | |
| SCHEMBL8055957 | 0.76 | PTGS2 (0.77) | PTGS2PTGS1KIF11 | |
| SCHEMBL21491267 | 0.75 | LMNA (0.51) | ERN1PTGS2TDP1 | |
| SCHEMBL5181460 | 0.75 | TDP1 (0.53) | ERN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080085-B1 | FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-08-14 | — | — | EP | disclosed |
| US-9815797-B2 | Fused bicyclic heteroaromatic derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2017-11-14 | — | — | US | disclosed |
| US-20160304470-A1 | Fused Bicyclic Heteroaromatic Derivatives As Modulators of TNF Activity | EVOTEC AG (DE) | 2016-10-20 | — | — | US | disclosed |
| EP-3080085-A1 | FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015086523-A1 | FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304470-A1 | Fused Bicyclic Heteroaromatic Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | ERN1 3716/4885PTGS2 293/4885TDP1 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.